Education
About Us
Working with TipRanks
Follow Us
MindWalk Holdings (DE:TQB0)
FRANKFURT:TQB0
TQB0 Stock Chart & Stats
€1.06
-€0.01(-2.24%)
At close: 4:00 PM EST
€1.06
-€0.01(-2.24%)
Day’s Range― - ―
52-Week Range€0.20 - €2.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)866.00
Market Cap
$50.49M
Enterprise Value€68.88M
Total Cash (Recent Filing)$14.18M
Total Debt (Recent Filing)$3.55M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Jul 23, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding46,691,280
10 Day Avg. Volume2,200
30 Day Avg. Volume866
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.83
P/FCF Ratio-2.80
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue3.78
Enterprise Value/Gross Profit6.33
Enterprise Value/Ebitda-6.49
Forecast
1Y Price Target
$4.33Price Target Upside308.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$14.40M
Bulls Say, Bears Say
Bulls Say
AI Drug-discovery PositioningLensAI's HYFT-based platform positions the company to capture growing demand from pharmaceutical developers for AI-driven discovery, supporting client expansion and strategic partnerships.
Pan-serotype Vaccine DifferentiationA vaccine candidate targeting a conserved functional epitope across serotypes enhances the prospect of broad protection, strengthening appeal to development partners and potential market differentiation.
Recurring Revenue TransitionEnterprise LensAI SaaS adoption validates the HYFT architecture and shifts sales toward subscription-like contracts, improving revenue predictability and margin scalability.
Bears Say
Commercial And Execution RiskAnalyst highlights that commercial challenges and execution failures could hinder market uptake of SaaS offerings and slow progress of development programs.
Competitive PressureAnalyst notes intense competition from established pharmaceutical companies and AI entrants could limit pricing power and market share for both drug candidates and software services.
Legal And Intellectual Property RiskAnalyst warns that legal issues or intellectual property disputes could lead to costly delays or limit freedom to operate for key programs.
MindWalk Holdings News
TQB0 FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was €0.20 and its highest was €2.80 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is $50.49M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Jul 23, 2026 which is in 130 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Mar 12, 2026. The company reported -€0.051 earnings per share for the quarter, missing the consensus estimate of -€0.034 by -€0.016.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.04.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 46,691,280 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -€0.051 in its last earnings report, missing expectations of -€0.034. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in DE:TQB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.33 (308.30% Upside)
$4.33 (308.30% Upside)
Blogger Sentiment
Bullish
DE:TQB0 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
206.17%
12-Months-Change
Fundamentals
Return on Equity
-63.13%
Trailing 12-Months
Asset Growth
-46.01%
Trailing 12-Months
Company Description
MindWalk Holdings
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
TQB0 Company Deck
TQB0 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and scientific positives: robust revenue growth (Q3 +52% YoY, nine-month +45%), U.S. revenue doubling, the signing of the first enterprise recurring Lens AI platform contract, important preclinical pipeline discoveries (conserved dengue epitope, influenza conserved feature, GLP-1 activity vs semaglutide), peer-reviewed validation, and a new nanobody platform launch. Offsetting these strengths are higher operating expenses (notably S&M and R&D), a Q3 gross margin dip, ongoing net losses and cash burn ($10.1M YTD), and dependency on pending preclinical readouts and successful asset-level financing. Overall, the highlights—revenue acceleration, platform monetization, and differentiated scientific milestones—materially outweigh the lowlights tied to investment-driven losses and program-stage risk.View all DE:TQB0 earnings summariesTQB0 Stock 12 Month Forecast
Average Price Target
€4.33
▲(308.30% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―
Options Prices
Currently, No data available
---